Patients with chronic kidney disease (CKD) have a high burden of atheromatous cardiovascular disease (ASCVD) that is not fully explained by traditional lipid parameters.
A study published in the clinical Kidney journal, conducted in patients with chronic kidney disease, reveals that information on lipoprotein composition and subclass particle number using the Liposcale test could improve the assessment of the risk of ASCVD.
